close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

15.02 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
Study Finds That the Mental Wellbeing Effects of Psilocybin Vary by Race
Via Investor Brand Network
New Study Shows Ibogaine Can Be Made Without Using Plant Matter
Via Investor Brand Network
News headline image
MindMed Appoints Matt Wiley as Chief Commercial Officer
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Present at Leerink’s Global Healthcare Conference 2025
From Mind Medicine Inc.
Via Business Wire
Groups of Military Veterans Urge Congress to Expedite Research on Psychedelics
Via Investor Brand Network
Topics Cannabis
News headline image
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed to Be Added to the Nasdaq Biotechnology Index
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
From Mind Medicine
Via Business Wire
News headline image
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed to Participate in Upcoming Investor Conferences
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Participate in September Investor Conferences
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
News headline image
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
From Mind Medicine Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today